BerandaBHM0 • FRA
add
BACHEM HOLDING AG
Tutup sebelumnya
€72,40
Rentang hari
€72,90 - €72,90
Rentang tahun
€51,25 - €81,50
Kapitalisasi pasar
5,16 M CHF
Volume Rata-Rata
27,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
SWX
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 191,04 jt | 4,70% |
Biaya operasional | 4,65 jt | -61,22% |
Penghasilan bersih | 49,35 jt | 17,36% |
Margin laba bersih | 25,83 | 12,11% |
Penghasilan per saham | — | — |
EBITDA | 63,83 jt | 9,45% |
Tarif pajak efektif | 1,53% | — |
Neraca
Total aset
Total liabilitas
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 30,99 jt | -67,45% |
Total aset | 2,11 M | 9,66% |
Total liabilitas | 650,41 jt | 22,28% |
Total ekuitas | 1,46 M | — |
Saham yang beredar | 74,94 jt | — |
Harga terhadap nilai buku | 3,72 | — |
Tingkat pengembalian aset | 5,95% | — |
Tingkat pengembalian modal | 8,26% | — |
Arus Kas
Perubahan kas bersih
| (CHF) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 49,35 jt | 17,36% |
Kas dari operasi | 92,80 jt | 220,31% |
Kas dari investasi | -89,05 jt | -624,68% |
Kas dari pembiayaan | -2,81 jt | -391,01% |
Perubahan kas bersih | 923,00 rb | -94,31% |
Arus kas bebas | -43,10 jt | -92,30% |
Tentang
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
CEO
Didirikan
1971
Situs
Karyawan
2.363